Sort
82,697 grants matching “vaccine development”
Lactoferrin as an Adjuvant for Cellular Immunity
$1,484,892Jeffrey K Actor · Pharmareview Corporation · R42 · FY2010 · AI
Stanford/UNC Biomimetic U19 Research Center
$1,484,612Calvin J Kuo · Stanford University · U19 · FY2024 · AI
Flavivirus Infections: Pathogenesis and Prevention
$1,484,329Francis Anthony Ennis · Univ Of Massachusetts Med Sch Worcester · P01 · FY2007 · AI
DNA AND PROTEIN IMMUNOGENS FOR SIV/HIV VACCINES
$1,483,964Emory University · P01 · FY2002 · AI
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
$1,483,918Ursula Buchholz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
DNA Vaccines
$1,483,911George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Development of Inhaled CPZEN-45 For Tuberculosis Therapy
$1,483,617Anthony James Hickey · Research Triangle Institute · R01 · FY2021 · AI
Task X15: Evaluation of Ebolavirus and Other Filovirus Vaccines in a Novel Animal Model
$1,483,578Randi Hornback · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2018 · AI
Dynamic single-cell analysis instrument to evaluate immune cell function
$1,483,544Laurence J.n. Cooper · Cellchorus Inc. · R44 · FY2024 · GM
SBIR TOPIC 255, PHASE II: SYNTHETIC VACCINES AGAINST PROSTATE CANCER
$1,483,094Peter Pushko · Medigen, Inc. · N44 · FY2011 · CA
Medical Scientist Training Program
$1,482,940Christopher S. Williams · Vanderbilt University · T32 · FY2022 · GM
Noroviruses and Epidemic Gastroenteritis
$1,482,839Kim Y. Green · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Env-Ab coevolution in SHIV infected RMs leading to V3 glycan bNAbs
$1,482,311George M Shaw · University Of Pennsylvania · P01 · FY2024 · AI
Comparative Study of Influenza Vaccines in Adults
$1,482,290Arnold S Monto · University Of Michigan At Ann Arbor · U01 · FY2006 · AI
VACCINES ADJUVANT DEVELOPMENT PROGRAM IN INFECTIOUS AND IMMUNE MEDIATED DISEASES
$1,481,691Tyson Heilherker · Boston Children'S Hospital · N01 · FY2024 · AI
Immunology, virology, and epidemiology of flaviviruses and other emerging viruses
$1,481,593Leah Katzelnick · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Mechanisms Of Humoral Evasion
$1,481,266Peter D Kwong · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
TASK X26: Immunogenicity and Efficacy Testing of Zika Vaccine Candidates in Animal Models
$1,481,147Randi Hornback · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2019 · AI
Clonal and imaging analyses of in vivo hematopoiesis, immune cell ontogeny and adoptive cell therapies
$1,481,031Cynthia E Dunbar · National Heart, Lung, And Blood Institute · ZIA · FY2021 · HL
Role of B Lymphocytes In HIV Infection And Pathogenesis
$1,480,637Susan Moir · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
UCSF HIV Clinical Trials Unit
$1,480,225Diane V Havlir · University Of California, San Francisco · U01 · FY2011 · AI
Tfh and B cells in HIV/SIV pathogenesis and vaccination
$1,479,880Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
HIV/SIV Replication In Vivo
$1,479,878Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Pre-Clinical Immunogenicity Testing of Chimp Adenovirus Vectors
$1,479,735Hildegund C. J. Ertl · Wistar Institute · U19 · FY2010 · AI
Chiang Mai University HIV/AIDS Clinical Trials Unit
$1,479,686Thira Sirisanthana · Chiang Mai University · U01 · FY2007 · AI